These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 27140404

  • 1. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M, Zeltsman M, McGee E, Adusumilli PS.
    Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
    [No Abstract] [Full Text] [Related]

  • 2. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
    Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.
    Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
    [Abstract] [Full Text] [Related]

  • 3. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [Abstract] [Full Text] [Related]

  • 4. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 5. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 6. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
    O'Hara M, Stashwick C, Haas AR, Tanyi JL.
    Immunotherapy; 2016 May 01; 8(4):449-60. PubMed ID: 26973126
    [Abstract] [Full Text] [Related]

  • 7. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH, Stashwick C, Plesa G, Tanyi JL.
    Immunotherapy; 2017 Aug 01; 9(9):767-780. PubMed ID: 28771103
    [Abstract] [Full Text] [Related]

  • 8. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.
    Mol Ther; 2019 Nov 06; 27(11):1919-1929. PubMed ID: 31420241
    [Abstract] [Full Text] [Related]

  • 9. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD.
    Cancer Immunol Res; 2019 Sep 06; 7(9):1412-1425. PubMed ID: 31337659
    [Abstract] [Full Text] [Related]

  • 10. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.
    Cancer Res; 2010 Nov 15; 70(22):9053-61. PubMed ID: 20926399
    [Abstract] [Full Text] [Related]

  • 11. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 12. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U.
    J Transl Med; 2013 Aug 12; 11():187. PubMed ID: 23937772
    [Abstract] [Full Text] [Related]

  • 13. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
    Morello A, Sadelain M, Adusumilli PS.
    Cancer Discov; 2016 Feb 12; 6(2):133-46. PubMed ID: 26503962
    [Abstract] [Full Text] [Related]

  • 14. CAR T-cell therapy for pancreatic cancer.
    DeSelm CJ, Tano ZE, Varghese AM, Adusumilli PS.
    J Surg Oncol; 2017 Jul 12; 116(1):63-74. PubMed ID: 28346697
    [Abstract] [Full Text] [Related]

  • 15. CAR T-cell therapy of solid tumors.
    Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH.
    Immunol Cell Biol; 2017 Apr 12; 95(4):356-363. PubMed ID: 28003642
    [Abstract] [Full Text] [Related]

  • 16. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM.
    Clin Cancer Res; 2011 Jul 15; 17(14):4719-30. PubMed ID: 21610146
    [Abstract] [Full Text] [Related]

  • 17. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
    Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, Li B, Lin S, Wang S, Wu Q, Liang Q, Li Y, Zhang X, Wu Y, Liu P, Yao Y, Pei D, Du X, Li P.
    J Hematol Oncol; 2017 Mar 13; 10(1):68. PubMed ID: 28288656
    [Abstract] [Full Text] [Related]

  • 18. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
    Hillerdal V, Ramachandran M, Leja J, Essand M.
    BMC Cancer; 2014 Jan 18; 14():30. PubMed ID: 24438073
    [Abstract] [Full Text] [Related]

  • 19. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
    Holzinger A, Abken H.
    Cancer Immunol Immunother; 2017 Nov 18; 66(11):1505-1507. PubMed ID: 28755091
    [No Abstract] [Full Text] [Related]

  • 20. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.
    JCI Insight; 2018 Apr 05; 3(7):. PubMed ID: 29618658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.